Zealand Pharma Updates Share Count and Voting Rights Information

Author: Dylan Bailey Updated: 09-30-2025 11:15 AM

Zealand Pharma's Share Count and Voting Rights Overview

Company announcement - No. 21 / 2025

Comprehensive Details on Shares and Voting Rights

Zealand Pharma A/S, a prominent player in the biotechnology sector, focuses on developing innovative peptide-based medications. As part of its transparency and compliance with the Danish Capital Markets Act, Zealand Pharma has provided updates regarding its share capital and voting rights as of the end of a recent month.

Amidst its ongoing growth and capital adjustments, Zealand Pharma announced a significant share capital increase following the exercise of employee warrants. This reflects the company's commitment to enhancing its capital structure and driving innovations in peptide medicines.

Key Financial Highlights

As per the latest data release, Zealand Pharma has reached a substantial milestone:

Total Shares: 71,364,728

This figure represents the nominal value of DKK 1 each. The share capital is also pegged at 71,364,728 DKK, aligning with the total number of shares. This highlights the company's robust capital base, which is pivotal for sustaining its research and development endeavors.

Voting Rights

Correspondingly, the total number of voting rights mirrors the number of shares, reaffirming a unified structure within the company. This attribute underscores the importance of shareholder engagement in the future direction of Zealand Pharma.

About Zealand Pharma A/S

Established in 1998 and headquartered in Copenhagen, Zealand Pharma A/S has made significant strides in the biotechnology field. Specializing in peptide-based therapeutics, the company has more than ten drug candidates advancing into clinical trials, with two already approved for market release. Their pipeline also includes three candidates that have reached late-stage development.

Zealand Pharma collaborates with various pharmaceutical companies, enhancing its reach and impact in the healthcare sector. This collaborative approach fosters innovation and supports the exploration of new therapeutic avenues, benefiting patients across the globe.

Presence and Expansion

With a solid presence in the United States alongside its Scandinavian roots, Zealand Pharma is well-positioned to navigate the global marketplace. The company’s strategic partnerships and alliances are crucial components in its pursuit of breakthroughs in peptide-based treatments, contributing to improved healthcare outcomes.

Contact Information for Investors

For those interested in learning more about Zealand Pharma's operations, the company has provided various contacts for inquiries:

Adam Lange
Vice President, Investor Relations
Contact: alange@zealandpharma.com

Neshat Ahmadi
Investor Relations Manager
Contact: neahmadi@zealandpharma.com

Rachel James-Owens
Vice President, Corporate Communications & Media Relations
Contact: RJamesOwens@zealandpharma.com

Frequently Asked Questions

What is the total number of shares for Zealand Pharma?

The total number of shares is 71,364,728, each with a nominal value of DKK 1.

How does the share count impact voting rights?

The number of voting rights equals the total number of shares, allowing shareholders to have a direct influence on company decisions.

What is Zealand Pharma's focus in the biotechnology field?

Zealand Pharma specializes in the discovery and development of peptide-based medicines, targeting various medical conditions.

When was Zealand Pharma founded?

Zealand Pharma was founded in 1998, establishing a footprint in the biotechnology industry.

How can investors contact Zealand Pharma for inquiries?

Investors can reach out to Adam Lange, Neshat Ahmadi, or Rachel James-Owens using the email addresses provided in this announcement.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.